Fertility on TRT: What the Research Actually Shows About hCG, hMG, and FSH Combinations

We've covered hCG's basic role in preserving fertility on TRT in an earlier article — replacing the LH signal TRT suppresses, keeping the testes active. This piece goes deeper into a more specific question: when hCG alone isn't enough, what does the actual comparative research show about adding hMG or FSH, and how do the real measured outcomes differ between these approaches? Why hCG Alone Sometimes Isn't Enough hCG mimics LH, which drives testosterone production locally within the testes. But sperm production (spermatogenesis) also depends on a second pituitary signal — FSH — that hCG doesn't replace on its own. This is precisely the gap that hMG and recombinant FSH are used to fill. What hMG Actually Is Human menopausal gonadotropin (hMG) is a purified gonadotropin preparation that supplies both LH-like and FSH activity, extracted originally from the urine of postmenopausal women (whose pituitary output of both hormones runs high). Because it supplies FSH activity that hCG doesn't, combining hCG with hMG is a way to address both halves of what the testes need — the LH-like signal for local testosterone production and the FSH signal for the sperm-producing (Sertoli cell) side of testicular function. The Real Comparative Data: hCG Alone vs. hCG Plus hMG This is where actual trial data — not just theory — gives a clear answer. According to PubMed, a randomized, open-label prospective study of 51 men with hypogonadotropic hypogonadism compared three approaches directly: hCG alone, combined hCG and hMG from the start, and hCG alone followed by combination therapy after six months. All three approaches produced significant increases in testicular volume, but the combination group had the largest increase. Testosterone levels also differed meaningfully by group — the combination group reached the highest mean maximum testosterone level, followed by the sequential group ([Sahib et al., Cureus, 2023, PMID: 37007338](https://doi.org/10.7759/cureus.35601)). The study's own conclusion was direct: hCG alone is sufficient to induce secondary sexual characteristics, but for fertility specifically, starting with combination therapy (or adding it in sequence) produced better results for spermatogenesis than hCG alone. The same study identified real factors that predicted worse outcomes regardless of which protocol was used: a BMI over 30, a small initial testicular volume (under 5 mL), and a treatment duration under 13 months were all associated with lower testosterone response — useful context for understanding that individual factors, not just the choice of medication combination, meaningfully affect outcomes and timelines. What Real-World Pregnancy Outcomes Look Like According to PubMed, a systematic review and meta-analysis pooling 20 studies and 709 men with congenital hypogonadotropic hypogonadism who didn't achieve natural conception after gonadotropin therapy (hCG combined with hMG, sometimes alongside pulsatile GnRH) and went on to use assisted reproductive technology found an overall effectiveness of 46% across the pooled studies, with a 73% pregnancy rate per embryo transfer cycle in the trials specifically measuring that outcome. Fertilization, implantation, and live birth rates showed no significant difference compared to infertility from other, unrelated causes ([Gao et al., BMC Endocrine Disorders, 2018, PMID: 30453944](https://doi.org/10.1186/s12902-018-0313-8)). The key takeaway from this data: even when gonadotropin therapy alone doesn't achieve natural conception, men who've been through hCG/hMG therapy aren't starting from a worse position than any other fertility patient once assisted reproduction is added — a genuinely reassuring finding for anyone worried that prior TRT or gonadotropin history permanently disadvantages later fertility treatment. What About Poor Responders? Not everyone responds adequately even to combination hCG/hMG therapy, and the research addresses this directly. According to PubMed, a study of 28 men with congenital hypogonadotropic hypogonadism who had a poor response to combined hCG/hMG therapy for a year or more were switched to pulsatile GnRH therapy instead — a different approach that stimulates the pituitary directly rather than replacing its downstream hormones. Sperm was detected in 60.7% of these previously poor-responding men after switching, with testicular size increasing further compared to their prior hCG/hMG treatment ([Huang et al., Archives of Endocrinology and Metabolism, 2024, PMID: 38739523](https://doi.org/10.20945/2359-4292-2023-0101)). This is genuinely useful information for anyone who doesn't see the expected response to hCG/hMG — it isn't necessarily the end of the road; a different mechanism (pulsatile GnRH, which requires a specialized pump device and specific clinical setting) has real, published success even in prior non-responders. Putting the Research Together The comparative data points in a consistent direction: hCG alone reliably restores testosterone and secondary sexual characteristics, but combination therapy with hMG (or FSH) more reliably supports the sperm-production side of fertility specifically, with real trial data showing better testicular volume and testosterone outcomes for combination approaches over hCG alone. For men who don't respond adequately even to combination gonadotropin therapy, pulsatile GnRH represents a genuinely different mechanism with documented success in exactly that poor-responder population. And for men who still don't achieve natural conception through any of these approaches, the research shows assisted reproductive technology offers comparable success rates to any other cause of infertility — not a diminished outlook because of prior TRT or hypogonadism history. The Bottom Line This is real, specific comparative research — not theoretical mechanism-stacking — and it supports a clear hierarchy of approaches depending on the actual goal: hCG alone for restoring testosterone and masculinizing effects, hCG combined with hMG (or FSH) when spermatogenesis and fertility specifically are the priority, and pulsatile GnRH as a documented option for men who don't respond adequately to gonadotropin combination therapy. None of this is a self-directed protocol — the specific combination, sequencing, and monitoring approach is exactly the kind of individualized decision that belongs with a reproductive endocrinologist or urologist tracking actual bloodwork and semen analysis over time, not a fixed formula applied the same way to everyone.